The Janssen Pharmaceutical Companies of Johnson & Johnson announced that the FDA has granted accelerated approval of Talvey (talquetamab-tgvs), a first-in-class bispecific antibody for the treatment of adult… read more.
The best heart rate for burning fat differs for each individual and often does not align with the “fat burning zone” on commercial exercise machines, Icahn School of… read more.
The quality of life of millions suffering from endometriosis – a painful disease where sensitive tissue grows outside of the uterus – could be improved by a new… read more.
The U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) voted unanimously 10 to 0 to recommend routine use of Sanofi and AstraZeneca’s… read more.
Restaurants can persuade patrons to choose healthier foods by adjusting the font size of numbers attached to nutritional information on menus, according to a study headed by a… read more.
On 26 May 2023, the European Medicine Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended revoking the conditional marketing authorization (MA) for crizanlizumab. On 3… read more.
New research from the Institute of Psychiatry, Psychology & Neuroscience (IoPPN) at King’s College London has demonstrated the safety and tolerability of a new drug treatment designed as… read more.
Astellas Pharma Inc announced the FDA approved Izervay (avacincaptad pegol intravitreal solution) for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD) on August 4,… read more.
Research from Saint Louis University School of Medicine finds that among patients 65 and older, a diagnosis of anxiety was significantly associated with an increased risk of dementia… read more.
There is a need to better deliver information on medical nutrition therapy for patients with Parkinson’s disease (PD). Findings of a new study in the Journal of Nutrition Education and Behavior,… read more.
Merck Inc announced that the FDA has approved an expanded indication for Ervebo, which is now indicated for the prevention of disease caused by Zaire ebolavirus in individuals… read more.
Between 7% and 15% of people in North America, between 5% and 9% of people in Europe, and between 1% and 5% of people in Asia suffer from… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
